This article will summarise the key studies in the field of acute leukaemia presented at the 2019 annual meeting of the American Society of Hematology (ASH). The selected abstracts in the field of acute myeloid leukaemia (AML) mainly focus on precision medicine, measurable residual disease (MRD) and maintenance treatment. In addition, results of the phase I trial using CD19/CD22 bispecific CAR T cells in paediatric and adult patients with acute lymphoblastic leukaemia (ALL) will be discussed.

(BELG J HEMATOL 2020;11(1):18–20)